Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL003 in chronic limb ischemia
CTR20221646Phase 3Completed
- Sponsor
- Northland Biotech
- Start
- Jul 2022
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Engensis in chronic limb-threatening ischaemia (CLTI), sponsored by Northland Biotech. Started Jul 2022; status: completed.
02
Drugs
Engensis
03
Conditions
chronic limb-threatening ischaemia (CLTI)
Beyond the preview
Go deeper on CTR20221646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221646.